Adaptive Biotechnologies Corporation

Informe acción NasdaqGS:ADPT

Capitalización de mercado: US$845.6m

Adaptive Biotechnologies Dirección

Dirección controles de criterios 2/4

El CEO de Adaptive Biotechnologies es Chad Robins , nombrado en Sep 2009, tiene una permanencia de 15.17 años. compensación anual total es $8.90M, compuesta por 7.4% salario y 92.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.23% de las acciones de la empresa, por valor de $10.40M. La antigüedad media del equipo directivo y de la junta directiva es de 6.2 años y 8.8 años, respectivamente.

Información clave

Chad Robins

Chief Executive Officer (CEO)

US$8.9m

Compensación total

Porcentaje del salario del CEO7.4%
Permanencia del CEO15.2yrs
Participación del CEO1.2%
Permanencia media de la dirección6.2yrs
Promedio de permanencia en la Junta Directiva8.8yrs

Actualizaciones recientes de la dirección

Recent updates

Adaptive Biotechnologies: Making Some Progress

Nov 26

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce

Nov 26
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce

Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Nov 01
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Oct 05
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Jul 12
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

May 08
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Apr 03
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Adaptive Biotechnologies: A Post Earnings Assessment

Feb 25

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Feb 17
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Feb 01
Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Nov 17
Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Oct 13
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Jul 06
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

May 05
Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Apr 15
We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Dec 13
Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system

Oct 11

Adaptive Biotechnologies announces $250M non-dilutive royalty financing

Sep 12

We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Aug 14
We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Apr 29
Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Adaptive Biotechnologies: Good Buy For Long-Term Investors

Apr 15

Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

Feb 26
Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chad Robins en comparación con los beneficios de Adaptive Biotechnologies?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

-US$195m

Jun 30 2024n/an/a

-US$213m

Mar 31 2024n/an/a

-US$215m

Dec 31 2023US$9mUS$663k

-US$225m

Sep 30 2023n/an/a

-US$196m

Jun 30 2023n/an/a

-US$191m

Mar 31 2023n/an/a

-US$195m

Dec 31 2022US$9mUS$658k

-US$200m

Sep 30 2022n/an/a

-US$221m

Jun 30 2022n/an/a

-US$232m

Mar 31 2022n/an/a

-US$229m

Dec 31 2021US$9mUS$639k

-US$207m

Sep 30 2021n/an/a

-US$190m

Jun 30 2021n/an/a

-US$171m

Mar 31 2021n/an/a

-US$155m

Dec 31 2020US$7mUS$597k

-US$146m

Sep 30 2020n/an/a

-US$122m

Jun 30 2020n/an/a

-US$99m

Mar 31 2020n/an/a

-US$82m

Dec 31 2019US$3mUS$493k

-US$70m

Sep 30 2019n/an/a

-US$62m

Jun 30 2019n/an/a

-US$56m

Mar 31 2019n/an/a

-US$53m

Dec 31 2018US$3mUS$423k

-US$46m

Compensación vs. Mercado: La compensación total de Chad($USD8.90M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.15M).

Compensación vs. Ingresos: La compensación de Chad ha aumentado mientras la empresa no es rentable.


CEO

Chad Robins (50 yo)

15.2yrs

Permanencia

US$8,904,267

Compensación

Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Chad Robins
Co-Founder15.2yrsUS$8.90m1.23%
$ 10.4m
Julie Rubinstein
President & COO6.8yrsUS$2.97m0.32%
$ 2.7m
Harlan Robins
Co-Founder & Chief Scientific Officer15.2yrsUS$8.61m0.69%
$ 5.9m
Sharon Benzeno
Chief Commercial Officer of Immune Medicine6.8yrsUS$2.88m0.22%
$ 1.9m
Christopher Carlson
Founderno datasin datossin datos
Kyle Piskel
VP, CFO & Principal Accounting Officer3.1yrsUS$1.66m0.10%
$ 884.3k
Karina Calzadilla
Vice President of Investor Relationsno datasin datossin datos
Francis Lo
Chief People Officer5.6yrssin datos0.17%
$ 1.5m
Susan Bobulsky
Chief Commercial Officer of MRD4.3yrssin datos0.17%
$ 1.5m
Mary Lancelotta
Senior Vice President of MRD BioPharma1.2yrssin datossin datos

6.2yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ADPT es experimentado (6.2 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Chad Robins
Co-Founder15.2yrsUS$8.90m1.23%
$ 10.4m
Peter Neupert
Lead Independent Director10.9yrsUS$355.00k0.093%
$ 790.6k
H. Parker
Member of Corporate Advisory Boardno datasin datossin datos
Michelle Griffin
Independent Director5.7yrsUS$330.00k0.035%
$ 297.7k
Robert Hershberg
Independent Director11.8yrsUS$325.00k0.051%
$ 435.3k
Michael Pellini
Independent Director6.8yrsUS$310.00k0.037%
$ 311.1k
Carol Gallagher
Member of Corporate Advisory Boardno datasin datossin datos
Craig Weissman
Member of Corporate Advisory Boardno datasin datossin datos
Graham Allen
Member of Corporate Advisory Boardno datasin datossin datos
Matthew Kahn
Member of Corporate Advisory Boardno datasin datossin datos
Katey Owen
Independent Director3.7yrsUS$310.00k0.038%
$ 321.6k

8.8yrs

Permanencia media

58.5yo

Promedio de edad

Junta con experiencia: La junta directiva de ADPT se considera experimentada (8.8 años de antigüedad promedio).